The Proteome of Bone Marrow Multipotent Mesenchymal Stromal Cells Undergoes Significant Alterations in Acute Leukemia Patients at the Onset and During Treatment.
In a small human observational study, bone-marrow mesenchymal stromal cells from patients with acute leukemia showed extracellular-matrix, mitochondrial, and vesicular-transport proteomic alterations at diagnosis and remission, whereas donor–patient differences were not detected around allo-HSCT.
Open original publication →What the AI sees
In a small human observational study, bone-marrow mesenchymal stromal cells from patients with acute leukemia showed extracellular-matrix, mitochondrial, and vesicular-transport proteomic alterations at diagnosis and remission, whereas donor–patient differences were not detected around allo-HSCT.
Research significance
The evidence identifies leukemia-associated stromal proteomic changes but does not test therapy; inferentially, persistent extracellular-matrix or mitochondrial dysfunction in the marrow niche could provide targets for restoring stromal support or modifying treatment response, subject to functional and clinical validation.
Source abstract
The bone marrow stromal microenvironment is damaged in patients with acute leukemia. The aim of this study was to analyze changes associated with the extracellular matrix, mitochondrial function, and vesicular transport in the proteome of multipotent mesenchymal stromal cells (MSCs) in patients at the onset, in remission, before, and 1-3 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study included paired MSCs samples from the bone marrow of 12 patients at the onset and in remission of acute leukemia (4 ALL, 8 AML) and eight patients before and after allo-HSCT (4 ALL, 4 AML). MSCs from eight healthy donors were used as a control. The growth characteristics and the proteome subsets describing extracellular matrix, mitochondria, and vesicular formation were studied. The proteome of the patients' MSCs differed significantly from that of the donor MSCs, both at the onset and in remission. Changes noted in the composition of extracellular matrix proteins may affect cell adhesion and access to growth factors. Significant changes were revealed in proteins affecting mitochondrial function. Vesicular transport proteins also differed between the donor and patient groups. Unexpectedly, no differences were found between the MSCs of donors and patients before and after allo-HSCT.